With this in mind, slight differences in GPER ligand sensitivity would be difficult to detect by IHC, however, measurement of GPER plasma membrane density by flow cytometric analysis of intact breast cancer cells (116) may provide a better handle as whether to apply anti-estrogen therapy in the context of GPER-targeted therapies described below. This evidence concerns the gene GPER1 and breast cancer.